A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.
The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?
Venture-backed companies are floating earlier, but time to takeout stays stubbornly steady.